6An overview of how CRISPR-Cas9 techniques could improve the efficiency of precise mutation in cells. About the Author: Martina Fabricci is a research scientist pursuing a PhD in immunogenomics with a MSc degree in Biotechnology and Molecular Biology with advanced courses from Harvard and MIT. She is the founder of CRISPR Biotech Engineering, a genome editing company. Martina conducts scientific research in the cellular engineering, biotechnology and genome editing fields. Her latest study was focused on the use of CRISPR-Cas9 in people to correct mutations that cause disease, using mainly two techniques. The first involves the development of the Cas9 system from bacteria that do not infect or cause immune responses within the human body. The other method involves tweaking endonuclease Cas9 enzymes to generate engineered forms of the enzyme that is capable of escaping immune responses within the body. Her key focus is on researching and understanding the various CRISPR-Cas9 applications, and exploring the promise it holds for researchers, students, scientists, as well as patients.